Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines

Mitchell, Daniel A.; Yong, Michelle C.R.; Raju, Jyothy; Willemsen, Nicole M.; Black, Matthew; Trent, Amanda; Tirrell, Matthew; Olive, Colleen

doi:10.4161/hv.7.0.14567

Cited by 15 publications

(10 citation statements)

References 45 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,38,39 Previous work in our laboratory has demonstrated several examples of PAs with clinical relevance, including systems for vaccines, 40,41 cancer, 33,42 and atherosclerosis theranostics. 1 Moreover, other groups report on the utility of PAs as matrices for regenerating tissue including nerves, 43 cartilage, 13 bone, 44 and enamel.…”

Section: Discussionmentioning

confidence: 98%

In vivo biodistribution and clearance of peptide amphiphile micelles

Chung

Mlinar

Sugimoto

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

In vivo biodistribution and clearance of peptide amphiphile micelles

Chung

Mlinar

Sugimoto

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

Self Cite

View full text Add to dashboard Cite

“…The type of PRR or unique combination of PRRs stimulated by a pathogen are responsible for controlling the outcome of the adaptive response, as is the case for the various PRR agonists. For example, most TLR agonists induce antibody and Th1 responses [238], although some can induce Th2 [255] and possibly Th17 responses [256]. Nod1 stimulation has also been shown to induce immunity with predominately a Th2 polarization profile [257].…”

Section: Prr Output and Design/choice Of Adjuvantmentioning

confidence: 98%

“…Nod1 stimulation has also been shown to induce immunity with predominately a Th2 polarization profile [257]. Studies have evaluated cytokine profiles induced in DCs after TLR stimulation with individual TLR agonists [256,258,259]; however, knowledge of the response outcomes including cytokine and chemokine signature profiles as well as the ratio of T-cell subtypes generated upon activation of combination PRRs is lacking, and would help in the design of vaccine formulations employing appropriate combination adjuvants in the future that can broaden the development of new vaccines against infectious diseases. Other issues for consideration when designing or choosing an adjuvant formulation are the vaccine antigen target and delivery system used as well as the route of vaccination.…”

Section: Prr Output and Design/choice Of Adjuvantmentioning

confidence: 99%

Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants

Olive

2012

Expert Review of Vaccines

Self Cite

119

View full text Add to dashboard Cite

The innate immune system plays an essential role in the host's first line of defense against microbial invasion, and involves the recognition of distinct pathogen-associated molecular patterns by pattern recognition receptors (PRRs). Activation of PRRs triggers cell signaling leading to the production of proinflammatory cytokines, chemokines and Type 1 interferons, and the induction of antimicrobial and inflammatory responses. These innate responses are also responsible for instructing the development of an appropriate pathogen-specific adaptive immune response. In this review, the focus is on different classes of PRRs that have been identified, including Toll-like receptors, nucleotide-binding oligomerization domain-like receptors, and the retinoic acid-inducible gene-I-like receptors, and their importance in host defense against infection. The role of PRR cooperation in generating optimal immune responses required for protective immunity and the potential of targeting PRRs in the development of a new generation of vaccine adjuvants is also discussed.

show abstract

“…These TLR agonists can be either large or small, and may contain either complete or only part of the agonist [95]. Although flagellin has been used for influenza vaccines, it is unlikely to be used in RA vaccines as it can exacerbate disease in mice with CIA [96].…”

Section: Composition Of Vaccinesmentioning

confidence: 99%

Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis

Rosenthal

Mikecz

Steiner

et al. 2015

Expert Review of Vaccines

View full text Add to dashboard Cite

The current status of therapeutic vaccines for autoimmune diseases is reviewed with rheumatoid arthritis as the focus. Therapeutic vaccines for autoimmune diseases must regulate or subdue responses to common self-antigens. Ideally, such a vaccine would initiate an antigen-specific modulation of the T-cell immune response that drives the inflammatory disease. Appropriate animal models and types of T helper cells and signature cytokine responses that drive autoimmune disease are also discussed. Interpretation of these animal models must be done cautiously because the means of initiation, autoantigens, and even the signature cytokine and T helper cell (Th1 or Th17) responses that are involved in the disease may differ significantly from those in humans. We describe ligand epitope antigen presentation system vaccine modulation of T-cell autoimmune responses as a strategy for the design of therapeutic vaccines for rheumatoid arthritis, which may also be effective in other autoimmune conditions.

show abstract

Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines

Cited by 15 publications

References 45 publications

In vivo biodistribution and clearance of peptide amphiphile micelles

In vivo biodistribution and clearance of peptide amphiphile micelles

Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants

Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis

Contact Info

Product

Resources

About